Objective: The aim of this study is to evaluate the liver metastasis risk among colorectal cancer patients with liver cirrhosis. Methods: This was a nationwide population-based cohort study of 2973 newly diagnosed colorectal cancer patients with liver cirrhosis and 11 892 age-sex matched controls enrolled in Taiwan between 2000 and 2010. The cumulative risk by Kaplan-Meier method, hazard ratio by the multivariate Cox proportional model and the incidence density were evaluated. Results: The median time interval from the colorectal cancer diagnosis to the liver metastasis event was 7.42 months for liver cirrhosis group and 7.67 months for non-liver cirrhosis group. The incidence density of liver metastasis was higher in the liver cirrhosis group (61.92/1000 person-years) than in the non-liver cirrhosis group (47.48/1000 person-years), with a significantly adjusted hazard ratio of 1.15 (95% CI = 1.04-1.28, P = 0.007). The 10-year cumulative risk of liver metastasis for the liver cirrhosis and the non-liver cirrhosis group was 27.1 and 23.6%, respectively (P = 0.006). For early cancer stage with locoregional disease patients receiving surgery alone without adjuvant anti-cancer treatments, patients with liver cirrhosis (10-year cumulative risk 23.9 vs. 15.7%, P < 0.001) or cirrhotic symptoms (10-year cumulative risk 25.6 vs. 16.6%, P = 0.009) both still had higher liver metastasis risk compared with their counterparts. For etiologies of liver cirrhosis, the 10-year cumulative risk for hepatitis B virus and hepatitis C virus, hepatitis B virus, hepatitis C virus, other causes and nonliver cirrhosis were 29.5, 28.9, 27.5, 26.7 and 23.4%, respectively, (P = 0.03). Conclusions: Our study found that liver metastasis risk was underestimated and even higher in colorectal cancer patients with liver cirrhosis.
Introduction
Liver cirrhosis (LC) is a serious disease that results in permanent damage to the liver. There are a variety of diseases and conditions that can cause cirrhosis of the liver. Alcoholic liver disease and hepatitis C are the most common causes in developed countries, whereas hepatitis B is the prevailing cause in most parts of Asia and sub-Saharan Africa (1) . The major clinical consequences of cirrhosis are impaired liver function, an increased intrahepatic resistance ( portal hypertension) and the development of hepatocellular carcinoma (1) . However, there are limited data in the literature on the incidence, prevalence and management of non-hepatic cancers (NHC) in cirrhotic patients (2, 3) . Previous studies suggested that LC might play a role in NHC metastasis, but the studies yield inconsistent results mainly due to limited sample sizes (4) (5) (6) .
Colorectal cancer is a worldwide health problem, particularly in developed countries, comprising 9.4% of all cancer cases with ∼1 million diagnoses annually worldwide (7) . It is also one of the leading causes of cancer related deaths in America, Europe and Asia (8) . In Taiwan, like in many other nations, colorectal cancer (CRC) is also a major public health problem. According to the report of the Bureau of Health Promotion, Taiwan, the CRC has become the most common malignancy in Taiwan since 2006 and the crude incidence rate was 60.62 per 100 000 people in 2010 (9) .
CRC cells travel to the liver through the hepatic portal circulation, and liver is the most common anatomical site for hematogenous metastasis (10) . Unlike other malignancy, the CRC patients with limited metastatic disease confined to the liver who are able to undergo resection may still have 25-37%, even 58%, chance of long-term survival (11, 12) . The National Comprehensive Cancer Network (NCCN) clinical practice guidelines in Oncology also suggested that hepatic resection is the treatment of choice for resectable liver metastasis (LM) from CRC (13, 14) . It was found that patients with an untreated single LM had a median survival of 19 months, with no patients surviving 5 years, while patients with a resected single LM had a median survival of 36 months with 25% of patients surviving 5 years (15) . By identifying risk factors of LM, it could be expected to find more resectable LM and achieve better outcomes.
The aim of this study was to estimate the effect of LC on risk of LM in CRC, which was one of the cancers likely to cause LM.
Patients and methods

Ethics statement
This study was reviewed and approved by the National Health Insurance Research Database (NHIRD) research committee and by the institutional review board (IRB no. B10104024) of Buddhist Dalin Tzu Chi Hospital. Informed consent was waived because the patients' personal identification numbers were de-identified.
Source of data
Patients were drawn from the NHIRD, released for research purposes by the National Health Research Institutes, Taipei, Taiwan (16) . This dataset provided all original claims data from the Taiwan National Health Insurance program, lunched since 1995, a mandatory-enrollment, single-payment system that financed healthcare for all Taiwanese citizens (>99% of the 24 million inhabitants of Taiwan) through a registry of board certified specialists and contracted medical facilities (∼97% of all Taiwan medical facilities) (17) . The NHIRD is one of the largest and most comprehensive databases in the world and has been used extensively in various studies (18) . For the precision of the claims data, the Bureau of National Health Insurance (BNHI) performs expert reviews on a random sample of every 50-100 ambulatory and every 20 inpatient claims in each hospital and clinic quarterly and interviews patients in order to verify the accuracy of diagnosis (19) . False reports of diagnosis would yield a severe penalty from the BNHI (20) . Therefore, information obtained from the NHIRD is considered to be complete and accurate (21) . The NHIRD provided information on encrypted patient identification numbers, sex, birthday, dates of admission and discharge, medical institutions providing the services, the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes of up to five diagnoses and procedures, respectively, outcome at hospital discharge (recovered, died or transferred out), order codes and the fees charged for medical services.
Study design and patients
This was a population-based cohort study, with the study period spanning from 1 January 2000 through 31 December 2010. We first identified patients with a diagnosis of CRC (ICD-9-CM codes 153.0 to 153.9 and 154.0 to 154.2) from inpatient and outpatient claims during the study period. These CRC patients must also have been issued catastrophic illness certificates that further ensure the accuracy of cancer diagnosis (21) . To ensure the inclusion of only newly diagnosed CRC between 2000 and 2010, patients who had a diagnosis of CRC between 1995 and 1999 were excluded. We further excluded patients with claims for any other malignancy (ICD-9-CM codes 140-208, excluding CRC) from 1995 to 2010, such as hepatocellular carcinoma. A total of 91 441 patients with newly diagnosed CRC were identified.
Among the 91 441 CRC patients, 2973 patients who had ICD-9-CM codes 571.2, alcoholic cirrhosis of liver, 571.5, cirrhosis of liver without mention of alcohol and 571.6, biliary cirrhosis, made in at least one inpatient or two outpatient medical records to make sure not a miscoding, before the initial diagnosis of CRC during the study period were defined to have a diagnosis of underlying liver cirrhosis (LC) in this study (22) . Because LC was prevalent in Taiwan, the government paid close attention to this health issue and has established specific guidelines for diagnosis and treatment of LC (23) . For each CRC patient with underlying LC, four CRC patients without LC were selected using frequency matching on age and gender, leading to 11 892 CRC patients without LC (Fig. 1) . Each study participant was followed until the occurrence of the following outcomes whichever comes first: (i) a diagnosis of LM (ICD-9-CM code 197.7) was made; (ii) the participant withdrew from the NHI system mainly due to death; and (iii) 31 December 2010.
LC severity and residual liver function information were evaluated by cirrhotic symptoms including ascites, jaundice, hepatic encephalopathy or albumin, frozen plasma (FP), flesh frozen plasma (FFP) transfusion.
Measurements of end-points and covariates
The primary dependent variable of interest was liver metastasis, including both synchronous and metachronous, which was identified from one inpatient or two outpatient claims. As mentioned above, we also excluded patients with claims for any other malignancy from 1995 to 2010 to rule out false LM events from hepatocellular carcinoma or other NHCs.
The covariates considered included gender, age at CRC diagnosis, hepatitis, comorbidities, clinical examinations, cancer treatment modalities, geographic region of living, urbanization level of residence and socioeconomic status. Hepatitis types included hepatitis B (ICD-9-CM codes 070.22, 070.23, 070.32, 070.33, V02.61) and hepatitis C (070.44, 070.54, V02.62). Comorbidities included diabetes mellitus (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401-405), hyperlipidemia (ICD-9-CM codes 272.0-272. 4) and chronic kidney disease (ICD-9-CM code 585). These comorbidities were adjusted for their possible role in liver microenvironment (24) (25) (26) . Geographic regions, urbanization level of residence and socioeconomic status information were adjusted for possible uneven medical resources to prevent information bias.
There were four geographic regions (northern, central, southern, eastern and other) in Taiwan. The urbanization level of residence was classified as seven levels based on five indices: population density, percentages of residences with college or higher education, percentages of residents >65 years old, percentages of residents who were agriculture workers and the number of physicians per 100 000 people (27) . Urbanization level of residence was further recorded as urban (Urbanization level 1), suburban (Urbanization levels 2-3) and rural (Urbanization levels 4-7) as per the National Statistics of Regional Standard Classification (28) . This study also used enrollee category, which can be used as a proxy measure of individual socioeconomic status (29) . All patients were categorized as high socioeconomic status (civil servants, full-time or regular paid personnel with a government affiliation, employees of privately owned institutions), middle (selfemployed individuals, other employees and members of the farmers' or fishermen's associations) and low socioeconomic status (veterans, members of low-income families and substitute service draftees) (30) .
Main and adjuvant cancer treatment modalities received by CRC patients depended on disease severity according to the NCCN clinical practice guidelines. This study adjusted cancer treatment modality types to reduce the potential for confounding by disease severity (Tables 1 and 2 ). Adjusted treatment modality types included surgery alone, surgery combining with concurrent chemoradiotherapy (CCRT), chemotherapy or radiotherapy or definite CCRT, chemotherapy alone, radiotherapy alone or supportive care alone.
Clinical cancer follow-up examinations were adjusted for avoiding potential disease surveillance/detection bias that patients with LC may be more likely receive frequent clinical examinations, such as abdominal sonography or computed tomography, than their non-LC counterparts, leading to an elevated risk of LM. Other clinical cancer examinations, such as tumor marker CEA and CA199 were also adjusted.
Statistical analysis
The statistical software packages SAS (version 9.2; SAS Institute, Inc., Cary, NC, USA) were used for data analysis. To assess the independent effects of LC on the risk of LM, we used Cox proportional hazard regression models, adjusting for the aforementioned potential confounders. The incidence density was calculated with person-years as the denominator under the Poisson assumption. Denominator of the incidence density was the sum of individual's person-years at-risk, namely from date of first ever CRC diagnosis to date of LM or censored. The Kaplan-Meier method was used to estimate the cumulative risk of LM. A two-sided P value < 0.05 was defined as statistically significant.
Results
Subject characteristics
The distributions of demographic characteristics and comorbidities for the CRC patients with and without LC are shown in Table 1 . Over 66% CRC patients with LC were male. The mean (±SD) age of patients with LC was 67.59 (±11.64). Compared with the non-LC patients, patients with LC had a significantly higher prevalence of comorbidities, which may have effect on liver microenvironment, including hepatitis, diabetes mellitus, hypertension, hyperlipidemia and chronic kidney disease. Most patients, both LC and non-LC groups, received surgery alone for CRC without adjuvant therapy. Compared with those without LC, lower percentage of patients with LC had cancer follow-up examinations, such as CEA, abdominal sonography and computed tomography examination, except CA199. Patients with LC were more likely to reside in the rural areas. A higher percentage of non-LC patients had high socioeconomic status and lived in northern Taiwan where more medical resources were available.
Risk of LM in CRC subjects with LC
The median time intervals from the CRC diagnosis to the LM event were 7.42 months for the LC group and 7.67 months for the non-LC group. The overall LM rates were 17.4 and 16.9% for the LC and non-LC group, respectively. Table 2 shows the incidence densities and hazard ratios (HRs) of LM in both groups. The incidence density of LM was higher in the LC group (61.92/1000 person-years) than in the non-LC group (47.48/1000 person-years), with a significantly increased adjusted HR of 1.15 (95% CI = 1.04-1.28, P = 0.007). The 10-year cumulative risk of LM for the LC and the non-LC group was 27.1 and 23.6%, respectively (P = 0.006, Fig. 2 ). Table 2 also shows HRs of LM according cirrhotic symptoms. Patients with various LC symptoms, including ascites, jaundice, hepatic encephalopathy or ever receiving albumin, frozen plasma (FP), flesh frozen plasma (FFP) transfusion all had higher incidence density of LM (64.66-91.91/1000 person-years) and increased adjusted HR of 1.07-1.38.
Significantly higher HRs of LM were associated with all other treatment modality, with a magnitude of HR ranging from 1.59 (surgery and chemotherapy, radiotherapy only) to 5.44 (chemotherapy alone), except surgery only (adjusted HR = 0.78, 95% CI = 0.68-0.89).
For patients who received surgery alone without adjuvant treatment, patients with LC had higher 10-year cumulative risk of LM (23.9 vs. 15.7%, P < 0.001; Fig. 3A) . We also compared patients with and without liver cirrhotic symptoms. We found that in the surgical alone group, CRC patients with cirrhotic symptoms, such as ascites, jaundice, hepatic encephalopathy or albumin, frozen plasma, flesh frozen plasma transfusion, had higher 10-year cumulative risk of LM (25.6 vs. 16.6%, P = 0.009; Fig. 3B ).
For etiology of LC, the 10-year cumulative risk for HBV and HCV, HBV, HCV, other causes and non-LC were 29.5, 28.9, 27.5, 26.7 and 23.4%, respectively, (P = 0.03; Fig. 4 ). Patients with both HBV and HCV infections showed the highest risk of LM.
Discussion
In this study, we found that non-LC patients had higher socioeconomic status and lived in northern Taiwan where more medical resources were available. Besides, patients with LC were also more likely to reside in rural area where the medical resources were less than in urban area. Patients with LC seemed to be a medical vulnerable group. For the cancer treatment, we did find that lower percentage of LC group ever received abdominal sonography or computed tomography than non-LC group, which was opposite to our thought that patients with LC should receive more examinations. We also found patients with LC had a significantly higher prevalence of comorbidities, including hepatitis, diabetes mellitus, hypertension, hyperlipidemia and chronic kidney disease. These comorbidities could further worse the health inequality.
The risk of LM in CRC patients with LC and cirrhotic symptoms in a hepatitis endemic nation
Taiwan is a nation characterized by high prevalence rates of infections by hepatitis B virus (HBV) and hepatitis C virus (HCV). It was estimated that some 17.3 and 4.4% of the general population were with seroprevalence of HBV and HCV, respectively (31) . Our data showed that 5.79% of CRC patients in Taiwan were also with clinical LC, which was much higher than the figure reported in an earlier US study in 1976-80 (0.15%) (32) . Liver is both the most frequent synchronous and metachronous metastatic site of CRC. A French study ever reported that the proportion of CRC patients with synchronous LM and the 5-year cumulative metachronous LM rate in CRC patients without LC mentioned were both 14.5% (33) . However, very few studies ever explored the relationship between LC and LM in patients with CRC (4-6) and suggested that LC is rare in CRC patients with LM and, vice versa, LM is rare in CRC patients with LC. A Japanese study showed that no LM was found in surgical CRC patients who suffered from LC (5) . In that study, LC was not found among the 40 patients with metastases but was present in 46 of the 210 nonmetastatic patients in their surgery department during past 5 years. Another Italian study which included 747 patients undergoing surgery for CRC in the surgery department, noted that synchronous LM were present in 32% of normal livers, but in 15% of fatty livers and 4.7% of patients with LC (4). However, for patients with clinical obvious cirrhotic symptoms, no studies yet ever studied the LM rate in this kind of patients. This cohort study showed the 10-year cumulative LM rate, including synchronous and metachronous, was 23.6% in normal liver, while 27.1% in cirrhotic liver. In further stratified analysis, surgery alone CRC patients with LC symptoms had higher 10-year cumulative LM risk than without symptoms (25.6 vs. 16.6%, P = 0.009).
Possible reason for low LM rate in other surgical studies: selection bias Several possible reasons may be responsible for the low LM rate observed in previous studies. First, both Italian and Japanese studies included only patients who received surgery in the surgery department. CRC patients with severe LC may not be referred to surgical department for hepatic metastasectomy because of poor reserved liver function (34) . Our nationwide population-based study would not have such selection bias problem. Secondary, the Italian study had more early cancer stage in LC patients while more Stage IV and nodal involvement in non-LC patients (P < 0.02 and P < 0.001), which would lead to less LM noted in cirrhotic liver just simply because a greater proportion of LC patients had earlier cancer stage disease. In this study, the cancer treatment modalities received by patients have been adjusted (Table 2) .
Possible underlying mechanisms
LC is an ongoing and chronic disease that can result in grave or lethal complications of other vital organs and body systems, such as digestive, circulatory, central nervous and immune systems. Our result implied a positive link between LC and LM. The etiology may include local microenvironment change or immune reaction change.
Mechanical factors may play a role such as that the mesenteric circulation and fenestrated capillaries of the liver facilitate hepatic metastasis (35) . Several studies have found a significantly increased intestinal permeability of small intestinal, gastroduodenal and whole intestine in patients with LC when compared with healthy subjects (36, 37) . There had been several indications for the presence of intestinal epithelial barrier dysfunction in patients with LC, especially in those with cirrhosis complications (38) . LC is also an advanced stage of liver fibrosis accompanied by vascular remodeling and distortion, which could lead to shunting of the portal and arterial blood supply directly into the hepatic outflow (central veins). Vascular distortion and blood speed deceleration may further facilitate cell seeding (1, 38) . Further investigations for the mechanism with which cirrhotic microenvironment change affects metastasis would help better understand the cancer metastasis process.
Study strength
Our study had several methodological strengths. First, the study subjects were collected from a nationwide population-based database. Our sample included all CRC patients receiving all kinds of cancer treatment modalities and eliminated the selection bias that severe LC patients may not receive hepatic surgery by clinical consideration. Second, nationwide insurance coverage minimized the potential for other selection bias, such as lost follow-up. Third, insurance claim records had information of medical treatments so that residual liver function and cirrhotic symptoms could be evaluated. There was no study yet ever investigating the relationship of cirrhotic symptoms and LM before this study.
Study limitations
Despite the above strengths, limitations were noted in our study. First, as other previous studies lacking cancer stage, such as the Japanese study etc., this study still lack such information. However, main and adjuvant cancer treatment modalities patients received were adjusted in this study. Furthermore, subgroup analysis showed that for patients receiving surgery alone without adjuvant anti-cancer treatments, who were mostly early cancer stage with only locoregional disease, patients with LC or cirrhotic symptoms still had higher LM risk. Second, in this study, only age and sex were matched without other characteristics such as comorbidities matched. Although this study design could allow these other characteristics to be analyzed, and discussed after regression adjustment to realize the difference of these two groups with and without LC, this was still a limitation for conclusion. Third, the diagnosis of LM was ICD-9-CM code 197.7, which was made by clinical physicians according to histologically defined or radiological criteria sometimes. However, LM misjudgment should have been minimized and could be ignored under the cancer treatment policy in Taiwan that cancer status dispute or treatment strategy changes would be confirmed later by multidisciplinary experts meeting to decide the subsequent treatment choices. Moreover, LM was confirmed by catastrophic illness certificates that further ensure the accuracy of cancer diagnosis. Other malignancy (ICD-9-CM codes 140-208, excluding CRC), such as hepatocellular carcinoma was also excluded to prevent the double malignancy condition.
Conclusion
Our study found that CRC patients with LC was a possible medical vulnerable group. LC prevalence is underestimated among CRC patients with LM in Taiwan and vice versa, LM risk is severely underestimated and even higher in CRC patients with LC. CRC patients with LC should be paid more attention about LM in clinical practice.
